The FEL (AF-4) protein donates transcriptional activation sequences to HRX-FEL fusion proteins in leukemias containing t(4;11)(q21;q23) chromosomal translocations

被引:13
|
作者
Morrissey, JJ
Raney, S
Cleary, ML
机构
[1] GOODWIN BIOTECHNOL INC,FT LAUDERDALE,FL 33313
[2] STANFORD UNIV,DEPT PATHOL,SCH MED,STANFORD,CA 94305
关键词
leukemia; chromosome translocation; Fel; HRX; transcriptional activation;
D O I
10.1016/S0145-2126(97)00012-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The t(4;11) chromosomal translocation marks a subset of acute lymphoblastic and secondary myeloid leukemias. It results in the fusion of the FEL (AF-4) gene on chromosome band 4q21 with the HRX(MLL) gene on chromosome band 11q23. This translocation results in the expression of fusion transcripts from both translocated chromosomes, with the derivative 11 product (fusing the amino-terminal third of the Hrx protein to the C-terminal two-thirds of the Fel protein) thought to be involved in leukemic transformation, The mechanism of transformation by Hrx-Fel in leukemic cells, however, is unknown and the specific leukemogenic contributions of Fel have not been defined, In this study, we demonstrate that Fel is capable of activating transcription from a minimal adenoviral E1b promoter as a Gal4-Fel fusion protein in transient transcriptional assays, The Fel transactivating sequences were localized to amino acids 365-572 which are consistently retained by Hrx-Fel fusion proteins created by t(4;11) translocations in leukemias. Furthermore, we demonstrate that the transactivation properties of Fel vary in different cell types, While Gal4-Fel constructs strongly activated transcription in Cos-7 cells and the MCF-7 breast tumor cell line, they displayed low to no activity in the precursor B-cell line REH, breast tumor cell line GI-101A and epithelial-derived A431 cells. These data are consistent with a potential role of Hrx-Fel as a chimeric transcription factor in which Fel contributes transcriptional effector properties and suggest the requirement for cell-specific accessory factors, (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:911 / 917
页数:7
相关论文
共 50 条
  • [41] Therapy-related acute lymphoblastic leukemia with t(4;11)(q21;q23) masqueraded as marrow lymphocytosis in a patient with breast cancer
    Chen, Yen-Hsun
    Hsieh, Yen-Chuan
    Lin, Shu-Hui
    Kuo, Szu-Yin
    Liu, Chiou-Ping
    Hwang, Wei-Shou
    Huang, Wen-Tsung
    Feng, Yin-Hsun
    Chuang, Shih-Sung
    Lin, Ching-Nan
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2012, 28 (03): : 173 - 177
  • [42] Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements
    Behm, FG
    Smith, FO
    Raimondi, SC
    Pui, CH
    Bernstein, ID
    BLOOD, 1996, 87 (03) : 1134 - 1139
  • [43] 46,XX,t(4;11)(q21;q23)成人急性淋巴细胞白血病(附病例报告)
    朱璐
    张美玲
    宋宗昌
    唐家宏
    实用医药杂志, 2011, 28 (08) : 692 - 693
  • [44] t(4;11)(q21;q23)特高白细胞急性双表型白血病一例
    朱翔
    李建勇
    吴雨洁
    张建富
    陆化
    白血病·淋巴瘤, 2009, (08) : 510 - 511
  • [45] Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23)
    M Hiwatari
    R Ono
    T Taki
    A Hishiya
    E Ishii
    T Kitamura
    Y Hayashi
    T Nosaka
    Leukemia, 2008, 22 : 2279 - 2280
  • [46] Translocation t(4;11)(q21;q23) and MLL gene rearrangement in acute lymphoblastic leukemia secondary to anti topoisomerase II anticancer agents
    Nasr, F
    MacIntyre, E
    Venuat, AM
    Bayle, C
    Carde, P
    Ribrag, V
    LEUKEMIA & LYMPHOMA, 1997, 25 (3-4) : 399 - 401
  • [47] Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23)
    Hiwatari, M.
    Ono, R.
    Taki, T.
    Hishiya, A.
    Ishii, E.
    Kitamura, T.
    Hayashi, Y.
    Nosaka, T.
    LEUKEMIA, 2008, 22 (12) : 2279 - 2280
  • [48] An infant with t(4;11)(q21;q23) acute lymphoblastic leukemia successfully treated using immunomagnetically purged autologous bone marrow transplantation
    Ohnishi, H
    Hayashi, Y
    Okamura, T
    Tabuchi, K
    Kobayashi, M
    Bessho, F
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (03): : 388 - 389
  • [49] MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?
    Britten, Oliver
    Ragusa, Denise
    Tosi, Sabrina
    Kamel, Yasser Mostafa
    CELLS, 2019, 8 (11)
  • [50] Pre-clinical in vitro evaluation of BCL-2 antisense compound Genasense™ (G3139; Genta, Inc.) as a targeted pro-apoptotic agent for leukemias with t(4;11)(q21;q23) translocations
    Robinson, BW
    Behling, KC
    Barrett, JS
    Gupta, M
    Rege, JM
    Moore, JS
    Bantly, AD
    Kim, J
    Hill, G
    Willman, CL
    Potter, J
    Adamson, PC
    Felix, CA
    BLOOD, 2005, 106 (11) : 939A - 939A